Clinical Trial of the Week: Phase II treatment study for breast cancer

By Donna Loyle, communications manager, LIMR

 

In this randomized phase II clinical trial, researchers are studying how well docetaxel or paclitaxel work in reducing chemotherapy-induced peripheral neuropathy in a patient cohort comprised of African American women diagnosed with stages I-III breast cancer.

 

Eligible participants must have had no prior taxane therapy and no prior or concurrent platinum-based chemotherapy. Also, they must have no pre-existing neuropathy.

 

Participants are grouped into two study arms:

  • Arm 1 receives paclitaxel IV once weekly. Treatment repeats every 21 days for 4 cycles.
  • Arm 2 receives docetaxel IV once every 3 weeks. Treatment repeats every 21 days.

 

Patients may also receive other medications at the physician’s discretion.

 

Study #EAZ171 is approved for all four MLH acute care hospitals. For more, email cancertrials@mlhs.org or visit https://www.mainlinehealth.org/research/clinical-trials/eaz171

This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Your email address will not be published.